Harald Reinhart - 25 Jun 2024 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Issuer symbol
ZLAB
Transactions as of
25 Jun 2024
Net transactions value
-$133,022
Form type
4
Filing time
27 Jun 2024, 16:09:27 UTC
Previous filing
05 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZLAB American Depositary Shares Options Exercise +18,250 +35% 70,050 25 Jun 2024 Direct F1, F2, F3
transaction ZLAB American Depositary Shares Sale $133,022 -7,431 -11% $17.90 62,619 26 Jun 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Restricted Share Units Options Exercise $0 -18,250 -33% $0.000000 36,500 25 Jun 2024 American Depositary Shares 18,250 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2 ADSs acquired upon vesting of Restricted Share Units ("RSUs").
F3 Each RSU represents a contingent right to receive one ADS.
F4 These ADSs were sold automatically to cover taxes upon vesting of RSUs.
F5 The RSUs vest in equal annual installments over four years beginning on 06/25/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.

Remarks:

President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases